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We report that H3K9 HMTase G9a activates transcription of the cell cycle regulatory gene, p21, in
p53-null H1299 cells. Positive regulation of p21 by G9a is independent of its HMTase activity. We
demonstrate that G9a upregulates p21 via interaction with PCAF, and provide evidence that the acti-
vating complex is recruited to the p21 promoter upon DNA damage-inducing agent etoposide treat-
ment. Our study suggests that G9a decreases proliferation and cell viability by increasing the level of
p21-mediated apoptosis. Our results suggest that G9a functions as a coactivator for p21 transcrip-
tion, and directs cells to undergo apoptosis.
Structured summary of protein interactions:
G9a physically interacts with PCAF by anti tag coimmunoprecipitation (1, 2) G9a physically interacts
with PCAF by anti bait coimmunoprecipitation (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction p53-independent mechanism. For example, p21 is upregulated dur-Methylation at Lys 9 of histone H3 (H3K9me1, 2, or 3) is in-
volved in gene repression and heterochromatin formation [1].
G9a (EHMT1, KMT1C) is the major histone lysine methyltransfer-
ase acting on both H3K9me1 and H3K9me2 in euchromatin [2].
Knockout of G9a leads to embryonic lethality in mice [3]. G9a is
a component of many repressive transcription complexes, includ-
ing Gﬁ1, UHRF1, CDP/Cut, and WIZ, and therefore has been inten-
sively studied in the context of its transcriptional corepressor
activity [4–7]. Furthermore, G9a has been shown to be overexpres-
sed in many types of cancers, with knockdown or inhibition of G9a
decreasing cellular proliferation [8–10]. In contrast to its repressive
role in gene expression, G9a can also act as a transcriptional coac-
tivator for certain nuclear receptor target genes, thereby inducing
cellular differentiation [11–14].
The regulatory protein, p21, belongs to the Cip/Kip family of cy-
clin dependent kinase (cdk) inhibitors and thus plays a major role
in cell cycle control [15]. Moreover, p21 also contributes to the
DNA damage response in processes such as cell cycle arrest and
apoptosis [16]. The main regulator of p21 is the tumor suppresser
gene, p53; p21 expression is upregulated by p53 in response
to DNA damage [17]. However, p21 can also be regulated by aing differentiation of murine erythroleukemia cells, which express
a mutated version of p53 [18]. Furthermore, p21 can also be in-
duced at the transcriptional level upon DNA damage by etoposide,
in a manner similarly independent from p53 [19].
In this study, we hypothesized that G9a functions as a positive
regulator of p21 expression via interaction with PCAF, and that G9a
is recruited to the p21 promoter upon cellular stress. Our results
indicate that etoposide-mediated induction of p21 expression in
p53-null cells is mediated by G9a, and that induction of p21 in this
context eventually inhibits cellular proliferation and leads to apop-
tosis. These results suggest that G9a can positively regulate expres-
sion of p21 upon cellular stress, and thereby inhibit cellular
proliferation, through a p53-independent mechanism.
2. Materials and methods
For details of ‘Materials and methods’ section; see Supplemen-
tary Data.
2.1. Plasmid constructs
pEGFP-C1, pEGFP-hG9a, pEGFP-hG9a-DSET, pcDNA3.0, pcDNA
3.0-Flag-G9a, Flag-G9a-685C, Flag-G9a-936C, pCMX-p300, pCMX-
CBP, and Flag-PCAF were used. The construct expressing short hair-
pin RNA (shRNA) directed against G9a (RHS4533-NM-006709) was
purchased from Open Biosystems.
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H1299, G9a knockdown stable H1299, K562, HCT116, and
HCT116 (p53/) cells were grown in RPMI 1640, and HEK293T
cells were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 10% heat inactivated fetal bovine serum and 0.05% pen-
icillin–streptomycin at 37 C in a 5% CO2 atmosphere. Cells were
treated either doxorubicin (3 lM) or etoposide (Sigma) (5 lM)
for 24 h. At 24 h post-transfection, cells were treated with the indi-
cated amount of BIX-01294 (Ann Arbor) for an additional 24 h, or
at 48 h post-transfection, cells were treated with either 5 lM eto-
poside or DMSO for an additional 24 h.
2.3. Luciferase assay
Luciferase assays were conducted using a p21 promoter repor-
ter system. H1229 cells were cotransfected with the p21 promoter
reporter construct and the indicated DNA constructs using Lipo-
fectamine 2000, or treated with 5 lM etoposide, for 24 h. After
transfection, cells were harvested and assayed for luciferase activ-
ity using a luciferase assay system (Promega). Each value was ex-
pressed as the mean of three replicates from a single assay, and
experiments were performed at least three times.
2.4. Immunoprecipitation (IP)
For the interaction assays, cells were lysed in lysis buffer
(20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, 1X protease inhibitor cocktail, and 1 mM PMSF) at
4 C. Proteins were immunoprecipitated with anti-GFP, anti-G9a,
or anti-PCAF antibodies overnight at 4 C, and then protein A/G
agarose beads (GenDEPOT) were added for 2 h with rotation at
4 C. Bound proteins were analyzed via Western blotting with
anti-GFP, anti-G9a, anti-PCAF, anti-Flag, anti-p300, and anti-CBP
antibodies.
2.5. Chromatin immunoprecipitation assay
H1299, K562, and HEK293T cells were treated with either 5 lM
etoposide or DMSO and harvested 24 h later. H1299 cells were
treated with 5 lM BIX-01294 and harvested 24 h later. Cells were
cross linked with 1% formaldehyde, which was added to the med-
ium for 10 min at RT, followed by the addition of 125 mM glycine
for 5 min at RT. Cells were then lysed in SDS lysis buffer, after
which samples were sonicated and immunoprecipitated using
the indicated antibodies. Immunoprecipitates were eluted and
cross links were reversed; subsequently, DNA fragments were
puriﬁed using a PCR puriﬁcation kit (Axygen). The following PCR
primers were used: p21 (forward, 50-GTG GCT CTG ATTGGC TTT
CTG-30; reverse, 50-CTG AAA ACA GGCAGC CCA AG-30). Disassocia-
tion curves were generated after each PCR run to ensure that a sin-
gle product of the appropriate length was ampliﬁed. The mean
threshold cycle (CT) and standard error values were calculated
from individual CT values, obtained from duplicate reactions per
stage. The normalized mean CT value was estimated as DCT by sub-
tracting the mean CT of the input from that of p21.
2.6. TUNEL assay
HEK293T cells were seeded in 4-well chamber slides and then
transiently cotransfected with pcDNA3.0-Flag-G9a and sh-G9a.
After 2 days, cells were treated with 10 lM etoposide for 24 h
and subsequently ﬁxed with 4% paraformaldehyde for 1 h at RT.
TUNEL (TdT-mediated dUTP nick end labeling) reactions were then
carried out using a DeadEndTM Fluorometric TUNEL System,
according to the manufacturer’s instructions (Promega).3. Results
3.1. G9a upregulates p21 expression
To gain insight into the role of the H3K9 HMTase, G9a, in cellu-
lar proliferation, we began by investigating whether G9a regulates
genes involved in cell cycle regulation. Initially, we examined the
effect of G9a overexpression on the levels of ING1, p27, GADD45b,
and p21 using real time PCR. As expected, G9a overexpression
downregulated ING1, p27, and GADD45b; in contrast, G9a overex-
pression upregulated p21 (Fig. 1A). Since G9a is well known for
its role in transcriptional repression [1], we further tested the reg-
ulation of p21 expression by G9a through shRNA-mediated gene
silencing. Using two different shRNA sequences, G9a knockdown
decreased both the mRNA and protein levels of p21 in H1299 cells
(Fig. 1B and C). Consistent result was obtained when p21 expres-
sion was tested in H1299 cells stably expressing G9a shRNA
(Fig. 1D). Intriguingly, a mutant version of G9a lacking the SET do-
main (G9a DSET) still upregulated p21 expression (Fig. 1B). Differ-
ent cell lines such as K562 and HEK293T were tested and showed
the consistent results (Supplementary Fig. S1A and S1B). To con-
ﬁrm the role of G9a HMTase activity for positive regulation of
p21, we examined the effect of BIX-01294, a G9a-speciﬁc inhibitor.
No apparent changes in p21 expression were measured by increas-
ing the concentration of BIX-01294 (Fig. 1E and Supplementary
Fig. S1C). These observations indicate that G9a-mediated upregula-
tion of p21 expression is independent of its HMTase activity.3.2. Transcriptional activation of p21 by G9a
To investigate the mechanism by which G9a upregulates p21
expression, we determined whether G9a activates the p21 pro-
moter using transient transfection of G9a in vitro. To this end, we
established a reporter assay using a p21-driven luciferase (luc) re-
porter system which enables quantiﬁcation of G9a-mediated tran-
scriptional modulation of p21. Consistent with our real time PCR
and Western blot results, p21 transcription was repressed by G9a
knockdown and activated by G9a overexpression in H1299 cells
(Fig. 2A). Using the G9a SET domain deletion mutant (G9a DSET),
we next veriﬁed that transcriptional activation of p21 by G9a
was independent of its HMTase activity (Fig. 2A). Since H1299 cells
are p53-null cells, harboring a homozygous partial deletion of p53,
these ﬁndings indicate that G9a positively regulates p21 transcrip-
tion by directly acting on the p21 promoter, independent of p53.
Using the same reporter assay in p53-positive HCT116 cells, we ob-
served that neither overexpression nor knockdown of G9a had an
effect on p21 expression (Fig. 2B and Supplementary S1D). Next,
we tested the effect of G9a on p21 activation induced by etopo-
side-mediated DNA damage. When H1299 cells were treated with
etoposide for 24 h, transcription of p21 was increased (Fig. 2C and
Supplementary S2A). Surprisingly, p21 activation by etoposide was
signiﬁcantly reduced by shRNA-mediated G9a knockdown
(Fig. 2C). This experiment was performed with two independent
shRNA sequences, to ensure that the observed effects were not
sequence-speciﬁc (Fig. 2C). Conversely, overexpression of G9a fur-
ther increased etoposide-mediated upregulation of p21 expression
(Fig. 2C). These results were also conﬁrmed on the protein level by
Western blot analysis, which showed that etoposide treatment in-
creased p21 protein levels and that G9a knockdown and overex-
pression in the presence of etoposide treatment either decreased
or further increased p21 levels, respectively (Fig. 2D). Western blot
analysis of HCT116 cell lysates revealed that p21 protein levels
were not altered in any of these conditions (data not shown).
When another DNA damaging agent doxorubicin was treated in
H1299 and HEK293T cells, same induction of p21 was observed
Fig. 1. Upregulation of p21 expression by G9a. (A) H1299 cells were transfected with GFP or GFP-G9a; subsequently, mRNA expression levels of ING1, p27, GADD45b, and p21
were examined by real time PCR. Results are shown as means ± S.D.s; n = 3. ⁄⁄P < 0.01. (B and C) H1299 cells were transfected with sh-CTL, sh-G9a#1, sh-G9a#2, GFP, GFP-G9a
(G9a WT), or GFP-G9a DSET, followed by analysis of mRNA and protein levels of p21 by real time PCR (B) and Western blotting (C). Protein expression levels of p21 were
quantiﬁed and normalized to the levels of b-actin. Results are shown as means ± S.D.s; n = 3. ⁄⁄⁄P < 0.001; ⁄⁄P < 0.01; ⁄P < 0.05. (D) The mRNA and protein levels of p21 in
H1299 cells stably expressing G9a shRNA were analyzed by real time PCR and Western blotting. Results are shown as means ± S.D.s; n = 3. ⁄⁄⁄P < 0.001. (E) H1299 cells were
transfected with the indicated constructs. At 24 h post-transfection, cells were treated with BIX-01294 (1.5 or 5 lM) for 24 h. Cell extracts were then analyzed by Western
blotting with the indicated antibodies.
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(Supplementary Fig. S2B). Taken together, these results demon-
strate that G9a has a p53-independent role in the DNA damage-
mediated transcriptional activation of p21.
3.3. G9a interacts with PCAF and is recruited to the p21 promoter
Previous studies have reported that G9a positively regulates
gene expression by acting as a transcriptional coactivator for
nuclear hormone receptors such as the androgen receptor, the
glucocorticoid receptor, and the estrogen receptor [11,14]. Since
our results indicated that G9a functions as a transcriptional
activator for p21, we decided to investigate whether G9a works
in concert with coactivators such as p300, CBP, and PCAF to
activate p21. To test this hypothesis, reporter assays were carriedout to investigate whether G9a works in concert with HATs. As
shown in Fig. 3A, p21 transcription was activated by G9a overex-
pression. When cells were cotransfected with G9a and PCAF, p21
transcription was further activated, but no apparent changes in
cotransfected cells with p300 or CBP (Fig. 3A). To further test
whether G9a interacts with HATs, IP assays were conducted. These
assays clearly showed that PCAF, but not p300/CBP, strongly inter-
acted with G9a, suggesting that G9a and PCAF form an activator
complex during p21 transcriptional activation (Fig. 3B). In vivo
interaction between endogenous G9a and PCAF was conﬁrmed by
IP using antibodies (Fig. 3C). We next performed domain mapping
of G9a and PCAF interaction. In vivo interactions between G9a and
PCAF were conﬁrmed by IP with transiently transfected cell ex-
tracts using PCAF antibodies (Fig. 3D). Interestingly, the G9a
685C (685–1210) deletion mutant with an intact ankyrin domain
Fig. 2. Transcriptional activation of p21mediated by G9a in the presence of etoposide. (A and B) H1299 cells and HCT116 cells were cotransfected with the p21 promoter-luc
construct and either the sh-CTL, sh-G9a#1, sh-G9a#2, GFP, GFP-G9a WT, or G9a DSET construct. (C) H1299 cells were cotransfected with the p21 promoter-luc construct and
either the sh-CTL, sh-G9a#1, sh-G9a#2, GFP, or GFP-G9a. At 48 h post-transfection, cells were treated with either 5 lM etoposide or DMSO for 24 h. Cell extracts were then
assayed for luciferase activity. Luciferase activities were normalized to those of b-galactosidase. Results are shown as means ± S.D.s; n = 3. ⁄⁄⁄P < 0.001. (D) H1299 cells were
transfected with the indicated constructs. At 48 h post-transfection, cells were treated with either 5 lM etoposide or DMSO for 24 h. Cell extracts were then analyzed by
Western blotting with the indicated antibodies.
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out ankyrin domain lost interaction with PCAF indicating that the
binding is dependent on the ankyrin domain of G9a (Fig. 3D). To
investigate further whether or not interaction between G9a and
PCAF is etoposide dependent, we monitored the interaction of
the two proteins with and without etoposide treatment. We have
been detected the basal level of interaction was strongly induced
by etoposide treatment (Fig. 3E and Supplementary Fig. S3A).
Intriguingly, very weak interaction was detected before etoposide
treatment and there was no induction of interaction in p53 intact
HCT116 cells which indicates the interaction is p53 independent
(Supplementary Fig. S3B).
To further elucidate the mechanism underlying p21 transcrip-
tional regulation by G9a and PCAF, we performed ChIP assay fol-
lowed by real time PCR. G9a and PCAF recruitment to the p21
promoter increased upon treatment with etoposide, as did the le-
vel of H3 acetylation (Fig. 3F and Supplementary Fig. S3C and
S3D). Interestingly, the level of H3K9me2 on the p21 promoter sig-
niﬁcantly decreased with etoposide treatment, suggesting that
H3K9 methyltransferase activity is not involved in this process
(Fig. 3F). These results indicate that G9a activates p21 expression
in a manner independent of its HMTase activity. Rather, G9a-med-
iated activation of p21 expression involves interaction with PCAF;
this activating complex is recruited to the p21 promoter, at least
in the context of etoposide-induced cell stress. When we tested
H3K9me2 recruitment on p21 promoter upon BIX-01294 treat-
ment, H3K9me2 level was unchanged because of the basal level
of G9a recruitment in the absence of etoposide (Supplementary
Fig. S3E).3.4. G9a inhibits cellular proliferation in the presence of etoposide
G9a is known to be overexpressed in many types of cancers, and
knockdown or inhibition of G9a has been shown to decrease cellu-
lar proliferation [8–10]. However, in our experiments, G9a posi-
tively activated p21 expression in p53-null cells. This ﬁnding
prompted us to verify that G9a regulates p21 and cellular prolifer-
ation upon etoposide-induced cellular stress in HEK293T cells, in
which p53 is inactivated by viral proteins [20]. First, we conducted
BrdU incorporation assays to measure cellular proliferation in the
presence of etoposide. As shown in Fig. 4A, overexpression of
G9a signiﬁcantly inhibited cellular proliferation, whereas knock-
down of G9a increased cellular proliferation. The observed inhibi-
tory effect on cell proliferation mediated by G9a was hardly
detected in the absence of etoposide treatment, indicating that
G9a is involved in the cellular stress response. Consistent results
were obtained in cell viability analyses, in which overexpression
of G9a decreased cell viability and shRNA-mediated knockdown
of G9a increased cell viability (Fig. 4B). The p53-null HCT116 cells
showed the same results in BrdU and cell viability assays (Supple-
mentary Fig. S4A and S4B). In contrast, no apparent changes were
observed when p53 intact HCT116 cells were used suggest that
p21-mediated apoptosis induction upon etoposide is p53 indepen-
dent (Supplementary Fig. S4C and S4D). Positive regulation of p21-
mediated apoptosis by G9a was also investigated by TUNEL assays.
The amount of apoptotic nuclei in DNase I-treated control and
etoposide-treated cells decreased upon knockdown of G9a by
different two shRNA sequences, a ﬁnding which supports the
hypothesis that G9a positively regulates p21-mediated apoptosis
Fig. 3. G9a interacts with PCAF and is recruited to the p21 promoter. (A) H1299 cells were cotransfected with the p21 promoter-luc construct and either GFP, GFP-G9a, GFP-
G9a and pCMX-p300, GFP-G9a and pCMX-CBP, or GFP-G9a and Flag-PCAF. Cell extracts were then assayed for luciferase activity. Luciferase activities were normalized to
those of b-galactosidase. Results are shown as means ± S.D.s; n = 3. ⁄⁄⁄P < 0.001. (B) HEK293T cells were cotransfected with GFP-G9a and Flag-PCAF, GFP-G9a and pCMX-p300,
or GFP-G9a and pCMX-CBP, and G9a was immunoprecipitated with anti-GFP antibodies. Associated proteins were analyzed by Western blotting with the indicated
antibodies. (C) Endogenous interaction between G9a and PCAF was examined in HEK293T cells. Cell lysates were immunoprecipitated with anti-G9a antibodies and
associated protein was analyzed by Western blotting with anti-PCAF antibodies. (D) HEK293T cells were cotransfected with Flag-PCAF and either full length (FL) or truncated
mutants of Flag-G9a (685C or 936C) constructs. Cell lysates were immunoprecipitated with anti-PCAF antibodies and associated protein was analyzed by Western blotting
with anti-Flag antibodies. (E) HCT116 (p53/) cells were transfected with GFP-G9a and Flag-PCAF. At 24 h post-transfection, cells were treated with either 5 lM etoposide
or DMSO for 24 h. Anti-GFP immunoprecipitates were analyzed via Western blotting with anti-Flag antibodies. (F) H1299 cells were treated with either 5 lM etoposide or
DMSO for 24 h. ChIP analysis was then conducted using anti-G9a, anti-H3K9me2, anti-PCAF, and anti-AcH3 antibodies. Recruitment of G9a, H3K9me2, PCAF, and AcH3 to the
p21 promoter region was normalized to the assay inputs. Anti-IgG antibodies were used as a negative control. Results are shown as means ± S.D.s; n = 3. ⁄⁄⁄P < 0.001;
⁄⁄P < 0.01; ⁄P < 0.05.
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proliferation and cell survival via upregulation of p21 transcription,
and induces p21-mediated apoptosis upon etoposide-induced
stress.4. Discussion
G9a is a member of the Suv39h subgroup of the SET domain-
containing proteins, and exhibits methylation speciﬁcity for
Fig. 4. Effect of G9a on etoposide-mediated apoptosis. (A) HEK293T cells were transfected with the indicated constructs upon etoposide treatment (5 lM). At 72 h post-
transfection, cells were ﬁxed and BrdU assays performed. Results are shown as means ± S.D.s; n = 3. ⁄P < 0.05; ⁄⁄⁄P < 0.001. (B) Cell viabilities were determined with the MTT
assay. HEK293T cells were treated with etoposide (5 lM) and subsequently transfected with the indicated constructs. Results are shown as means ± S.D.s; n = 3. ⁄⁄P < 0.01;
⁄⁄⁄P < 0.001 compared with untreated cells. (C) HEK293T cells, transiently transfected with the indicated constructs upon etoposide treatment (5 lM), were subjected to
TUNEL assays. DNase I-treated cells are shown as a positive control.
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which mediate H3K9me1, H3K9me2, and H3K27 methylation
and are also linked with heterochromatin formation and transcrip-
tional repression [1,2]. Although various roles of G9a have been
proposed in diverse biological processes and human diseases, the
function of G9a in cellular proliferation remains poorly under-
stood. In this study, we discovered that G9a positively regulates
p21 expression, at the transcriptional level, in p53-null cells, indi-
cating that G9a-mediated activation of p21 is p53-independent.
Furthermore, knockdown of G9a decreased p21 promoter activity
in a SET-domain-, HMTase activity- independent manner.
It is intriguing that G9a has different domains which mediate
activation and inhibition of transcription. G9a positively regulates
transcription mediated by various nuclear receptors, including
the steroid, estrogen, and glucocorticoid receptors, through a
HMTase-independent mechanism [11,13]. It is possible that the
previously characterized N-terminal domain of G9a, containing
its transcriptional activation domain, mediates its transcriptional
activation of p21. We further investigated the role of G9a in p21
activation upon etoposide-induced DNA damage. Using p21-luc
reporter and ChIP assays, we showed that G9a increased the
promoter activity and expression of p21 in p53-null H1299 cells;
furthermore, we demonstrated that G9a was recruited to the p21
promoter upon etoposide treatment. We also identiﬁed an
interaction between G9a and PCAF which contributes to the
transcriptional activation of p21, and showed that this complex is
recruited to the p21 promoter upon etoposide treatment. These
results suggest that G9a and the PCAF HAT complex are bothphysically and functionally associated in the transcriptional activa-
tion of p21. Both ChIP assays and real time PCR analysis showed
that the level of H3K9me2 on the p21 promoter signiﬁcantly de-
creased, even though G9a recruitment was increased, in the pres-
ence of etoposide. This result indicates that activation of p21
expression by G9a does not depend on its H3K9 HMTase activity,
rather, suggests possible involvement of H3K9me2 demethylase.
Coordinated epigenetic repression of p21 has previously been
reported, involving a transcriptional regulator, Gﬁ1. Gﬁ1 has been
shown to recruit G9a and HDAC1 to the p21 promoter, thereby
repressing its expression in HL-60 cells [4]. Another study sug-
gested that the RING-ﬁnger E3 ubiquitin ligase, UHRF1, is a tran-
scriptional corepressor that functions to recruit G9a and other
chromatin-modifying enzymes to the p21 promoter [5]. In these
studies, H3K9 HMTase activity was shown to play a critical role
in the recruitment of corepressors such as HDAC and DNMT and
thereby facilitate transcriptional repression of target genes.
The effect of p21 upregulation by G9a was also monitored via
cellular viability, proliferation, and apoptosis analyses. These
experiments indicated that G9a negatively regulates cellular via-
bility and proliferation by inducing p21-mediated apoptosis in
the presence of etoposide. These observations suggest that the role
of G9a in upregulation of p21 is potentiated under stress condi-
tions. In summary, our data demonstrate an additional role of
G9a as a transcriptional coactivator that is recruited with PCAF to
the p21 promoter, and suggest that G9a plays dual functions in
transcriptional regulation, which are in turn regulated by various
chromatin modiﬁers.
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